New hope for an aids vaccine

Nature Reviews Immunology

Volumn 2, Issue 4, 2002, Pages 239-250

  Robinson, Harriet L ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANTIGEN; DNA VACCINE; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 2; LIVE VACCINE; MICROSPHERE; POL PROTEIN; RECOMBINANT GLYCOPROTEIN GP 120; SODIUM CHLORIDE; SUBUNIT VACCINE; VIRUS ENVELOPE PROTEIN; VIRUS RNA; VIRUS VECTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADENO ASSOCIATED VIRUS; ALPHA VIRUS; CELLULAR IMMUNITY; CLINICAL TRIAL; CODON; CODON OPTIMIZATION; CORRELATE OF PROTECTION; DRUG DESIGN; EXPRESSION VECTOR; GENE GUN; HELPER CELL; HERPES VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; INFECTION CONTROL; LIVE VIRUS VECTOR; MONKEY; NONHUMAN; PICORNAVIRUS; POXVIRUS; PRIME BOOST; PRIORITY JOURNAL; PROCESS OPTIMIZATION; REVIEW; RHABDOVIRUS; RNA ANALYSIS; VACCINE PRODUCTION; VACCINIA VIRUS; VIRAL SET POINT; VIRUS RECOMBINANT; ANIMAL; CD8+ T LYMPHOCYTE; FORECASTING; GENE VECTOR; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; MACACA;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS VACCINES; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CLINICAL TRIALS; DRUG DESIGN; FORECASTING; GENETIC VECTORS; HIV-1; HUMANS; MACACA; VACCINES, DNA;

EID: 0036547263     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri776     Document Type: Review

References (117)

1. Barre-Sinoussi, F. et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220, 868-871 (1983).
2. Popovic, M., Sarngadharan, M. G., Read, E. & Gallo, R. C. Detection, isolation and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 224, 497-500 (1984).
3. Ratner, L. et al. Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature 313, 277-284 (1985).
4. Gorrlich, M. S. et. al. in Morbidity and Mortality Weekly Report 250-252 (US Centers for Disease Control and Prevention, Atlanta, 1981).
5. Kwong, P. D. et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393, 648-659 (1998).
6. Myszka, D. G. et al. Energetics of the HIV gp120-CD4 binding reaction. Proc. Natl Acad. Sci. USA 97, 9026-9031 (2000).
7. Parren, P. W., Moore, J. P., Burton, D. R. & Sattentau, Q. J. The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity. AIDS 13, S137-S162 (1999).
8. Finzi, D. & Silliciano, R. F. Viral dynamics in HIV-1 infection. Cell 93, 665-671 (1998).
9. + T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nature Med. 5, 512-517 (1999).
10. Ramratnam, B. et al. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged antiretroviral therapy. Nature Med. 6, 82-85 (2000).
11. McCutchan, F. E. Understanding the genetic diversity of HIV-1. AIDS 14, S31-S44 (2000).
12. Korber, B. et al. Evolutionary and immunological implications of contemporary HIV-1 variation. Br. Med. Bull. 58, 19-42 (2001).
13. Gao, F. et al. Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature 397, 436-441 (1999).
14. Peeters, M. in HIV Molecular Immunology 2000 (eds Korber, B. et al.) 139-154 (Los Alamos National Laboratory, Los Alamos, 2000).
15. Preston, B. D. Reverse transcriptase fidelity and HIV-1 variation. Science 275, 228-229 (1997).
16. Ho, D. D. et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373, 123-126 (1995).
17. Evans, D. T. et al. Virus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and Nef. Nature Med. 5, 1270-1276 (1999).
18. + cells in human immunodeficiency virus type I pathogenesis: cytolytic and noncytolytic inhibition of viral replication. Adv. Immunol. 66, 273-311 (1997).
19. McMichael, A. J. & Rowland-Jones, S. L. Cellular immune responses to HIV. Nature 410, 980-987 (2001).
20. Korber, B. et al. (eds) HIV Molecular Immunology 2000, II1-IIC32 (Theoretical Biology and Biophysics Group, Los Alamos, New Mexico, 2000).
21. + T cells. Immunol. Today 17, 217-224 (1996).
22. + T-cell-mediated suppression of HIV replication: β-chemokine-dependent and -independent effects. AIDS Res. Hum. Retroviruses 13, 63-69 (1997).
23. + T-cell-mediated suppressive activity inhibits HIV-1 after virus entry with kinetics indicating effects on virus gene expression. Proc. Natl Acad. Sci. USA 97, 3503-3508 (2000).
24. Pal, R. et al. Inhibition of HIV-1 infection by the β-chemokine MDC. Science 278, 695-698 (1997).
25. Garzino-Demo, A., DeVico, A. L., Cocchi, F. & Gallo, R. C. β-chemokines and protection from HIV type 1 disease. AIDS Res. Hum. Retroviruses 14, S177-S184 (1998).
26. Phillips, R. E. et al. Human immunodeficiency virus genetic variation that can escape cytotoxic T-cell recognition. Nature 354, 453-459 (1991).
27. Borrow, P. et al. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nature Med. 3, 205-211 (1997).
28. + lymphocytes. Science 283, 857-860 (1999).
29. Jin, X. et al. Dramatic rise in plasma viremia after CD8(+) T-cell depletion in simian immunodeficiency virus-infected macaques. J. Exp. Med. 189, 991-998 (1999).
30. Baba, T. W. et al. Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science 267, 1820-1825 (1995).
31. Baba, T. W. et al. Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques. Nature Med. 5, 194-203 (1999).
32. Barouch, D. H. et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 290, 486-492 (2000). The first report of the control of SHIV-89.6P challenge by a predominantly T-cell response.
33. Amara, R. R. et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292, 69-74 (2001). A demonstration of the ability of the memory response that is raised by parenteral DNA or MVA immunizations to control a mucosal SHIV-89.6P challenge.
34. Shiver, J. W. et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency virus immunity. Nature 415, 331-335 (2002). A description of the ability of DNA-Ad5 and Ad5 to achieve control with only Gag expression.
35. Barouch, D. H. et al. Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination. J. Virol. 75, 5151-5158 (2001).
36. + lymphocyte depletion in rhesus monkeys. J. Virol. 71, 4216-4225 (1997).
37. Mellors, J. W. et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272, 1167-1170 (1996).
38. Barouch, D. H. et al. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature 415, 335-339 (2002).
39. Quinn, T. C. et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N. Engl. J. Med. 342, 921-929 (2000).
40. Panicali, D. & Paoletti, E. Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus. Proc. Natl Acad. Sci. USA 79, 4927-4931 (1982).
41. Mackett, M., Smith, G. L. & Moss, B. Vaccinia virus: a selectable eukaryotic cloning and expression vector. Proc. Natl Acad. Sci. USA 79, 7415-7419 (1982).
42. Tang, D. C., De Vit, M. & Johnston, S. A. Genetic immunization is a simple method for eliciting an immune response. Nature 356, 152-154 (1992).
43. Robinson, H. L., Hunt, L. A. & Webster, R. G. Protection against a lethal influenza virus challenge by immunization with a haemagglutinin-expressing plasmid DNA. Vaccine 11, 957-960 (1993).
44. Ulmer, J. B. et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259, 1745-1749 (1993).
45. MacGregor, R. R. et al. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J. Infect. Dis. 178, 92-100 (1998).
46. Freed, E. O. & Martin, M. A. in Fields Virology, Vol. 2 eds Knipe, D. M. & Howley, P. M.) 1971-2041 (Lippincott, Williams & Wilkins, Philadelphia, 2001).
47. Lu, S., Santoro, J. C., Fuller, D. H., Haynes, J. R. & Robinson, H. L. Use of DNAs expressing HIV-1 Env and noninfectious HIV-1 particles to raise antibody responses in mice. Virology 209, 147-154 (1995).
48. Zur Megede, J. et al. Increased expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 gag gene. J. Virol. 74, 2628-2635 (2000).
49. Huang, Y., Kong, W. P. & Nabel, G. J. Human immunodeficiency virus type-1-specific immunity after genetic immunization is enhanced by modification of Gag and Pol expression J. Virol. 75, 4947-4951 (2001).
50. Pontesilli, O. et al. Longitudinal analysis of human immunodeficiency virus type-1-specific cytotoxic T-lymphocyte responses: a predominant Gag-specific response is associated with nonprogressive infection. J. Infect. Dis. 178, 1008-1018 (1998).
51. Cohen, A. D., Boyer, J. D. & Weiner, D. B. Modulating the immune response to genetic immunization. FASEB J. 12, 1611-1626 (1998).
52. Singh, M., Briones, M., Ott, G. & O'Hagan, D. Cationic microparticles: a potent delivery system for DNA vaccines. Proc. Natl Acad. Sci. USA 97, 811-816 (2000).
53. Widera, G. et al. Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J. Immunol. 164, 4635-4640 (2000).
54. Barouch, D. H. et al. Augmentation and suppression of immune responses to an HIV-1 DNA vaccine by plasmid cytokine/Ig administration. J. Immunol. 161, 1675-1682 (1998).
55. Davis, N. L. et al. Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles. J. Virol. 74, 371-378 (2000).
56. Rose, N. F. et al. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 106, 539-549 (2001).
57. Murphy, C. G. et al. Vaccine protection against simian immunodeficiency virus by recombinant strains of herpes simplex virus. J. Virol. 74, 7745-7754 (2000).
58. Liu, X. L., Clark, K. R. & Johnson, P. R. Production of recombinant adeno-associated virus vectors using a packaging cell line and a hybrid recombinant adenovirus. Gene Ther. 6, 293-299 (1999).
59. Andino, R. et al. Enginerring poliovirus as a vaccine vector for the expression of diverse antigens. Science. 265, 1448-1451 (1994).
60. + T cells develop after intragastric vaccination with a Salmonella Env DNA vaccine vector. Vaccine 20, 623-629 (2001).
61. Mayr, A., Hochstein-Mintzel, V. & Stickl, H. Abstammung, Eigenschaften und Verwendung des Attenuierten Vaccinia-stammes MVA. Infection 3, 6-14 (1975).
62. Mayr, A., Stickl, H., Muller, H. K., Danner, K. & Singer, H. The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism. Zentralbl. Bakteriol. [B] 167, 375-390 (1978).
63. Antoine, G., Scheiflinger, F., Dorner, F. & Falkner, F. G. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 244, 365-396 (1998).
64. Blanchard, T. J., Alcami, A., Andrea, P. & Smith, G. L. Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. J. Gen. Virol. 79, 1159-1167 (1998).
65. Anderson, K. P. & Fennie, E. H. Adenovirus early region 1A modulation of interferon antiviral activity. J. Virol. 61, 787-795 (1987).
66. Gutch, M. J. & Reich, N. C. Repression of the interferon signal transduction pathway by the adenovirus E1A oncogene. Proc. Natl Acad. Sci USA 88, 7913-7917 (1991).
67. Reich, N., Pine, R., Levy, D. & Darnell, J. E. Jr. Transcription of interferon-stimulated genes is induced by adenovirus particles but is suppressed by E1A gene products. J. Virol. 62, 114-119 (1988).
68. Andersson, M., McMichael, A. & Peterson, P. A. Reduced allorecognition of adenovirus-2-infected cells. J. Immunol. 138, 3960-3966 (1987).
69. Burgert, H. G., Maryanski, J. L. & Kvist, S. "E3/19K" protein of adenovirus type 2 inhibits lysis of cytolytic T lymphocytes by blocking cell-surface expression of histocompatibility class I antigens. Proc. Natl Acad. Sci. USA 84, 1356-1360 (1987).
70. Gooding, L. R., Elmore, L. W., Tollefson, A. E., Brady, H. A. & Wold, W. S. A 14,700 MW protein from the E3 region of adenovirus inhibits cytolysis by tumor necrosis factor. Cell 53, 341-346 (1988).
71. Duerksen-Hughes, P. J., Hermiston, T. W., Wold, W. S. & Gooding, L. R. The amino-terminal portion of CD1 of the adenovirus E1A proteins is required to induce susceptibility to tumor necrosis factor cytolysis in adenovirus-infected mouse cells. J. Virol. 65, 1236-1244 (1991).
72. Carroll, M. W. & Moss, B. Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology 238, 198-211 (1997).
73. Fallaux, F. J. et al. New helper cells and matched early region-1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum. Gene Ther. 9, 1909-1917 (1998).
74. Sutter, G. & Moss, B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl Acad. Sci. USA 89, 10847-10851 (1992).
75. Chakrabarti, S., Sisler, J. R. & Moss, B. Compact, synthetic, vaccinia virus early/late promoter for protein expression. Biotechniques 23, 1094-1097 (1997).
76. Zhong, L. et al. Presentation of SIVgag to monkey T cells using dendritic cells transfected with a recombinant adenovirus. Eur. J. Immunol. 30, 3281-3290 (2000).
77. Zhong, L., Granelli-Piperno, A., Choi, Y. & Steinman, R. M. Recombinant adenovirus is an efficient and non-perturbing genetic vector for human dendritic cells. Eur. J. Immunol. 29, 964-972 (1999).
78. Ginsberg, H. S. et al. A mouse model for investigating the molecular pathogenesis of adenovirus pneumonia. Proc Natl Acad. Sci. USA 88, 1651-1655 (1991).
79. Farina, S. F. et al. Replication-defective vector based on a chimpanzee adenovirus. J. Virol. 75, 11603-11613 (2001).
80. Henderson, D. A. & Moss, B. Smallpox and Vaccinia (W. B. Saunders, Philadelphia, 1999).
81. + T cells using heterologous prime-boost immunisation strategies. Immunol. Rev. 170, 29-38 (1999).
82. Ramshaw, I. A. & Ramsay, A. J. The prime-boost strategy: exciting prospects for improved vaccination. Immunol. Today 21, 163-165 (2000).
83. Robinson, H. L., Smith, J. M., Amara, R. R. AIDS vaccines: heterologous prime/boost strategies for raising protective T-cell responses. AIDS Rev. 2, 105-110 (2000).
84. + T-cell-mediated protective immunity against malaria. Proc. Natl Acad. Sci. USA 90, 5214-5218 (1993).
85. Lu, S. et al. Simian immunodeficiency virus DNA vaccine trial in macaques. J. Virol. 70, 3978-3991 (1996).
86. Robinson, H. L. et al. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunization. Nature Med. 5, 526-534 (1999).
87. Boyer, J. D. et al. Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination. Nature Med. 3, 526-532 (1997).
88. Haigwood, N. L. et al. Protection from pathogenic SIV challenge using multigenic DNA vaccines. Immunol. Lett. 66, 183-188 (1999).
89. Habel, A. et al. DNA vaccine protection against challenge with simian/human immunodeficiency virus 89.6 in rhesus macaques. Dev. Biol. (Basel) 104, 101-105 (2000).
90. Fynan, E. F. et al. DNA vaccines: protective immunizations by parenteral, mucosal and gene-gun inoculations. Proc. Natl Acad. Sci. USA 90, 11478-11482 (1993).
91. Feltquate, D. M., Heaney, S., Webster, R. G. & Robinson, H. L. Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization. J. Immunol. 158, 2278-2284 (1997).
92. Hanke, T. et al. Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen. J. Virol. 73, 7524-7532 (1999).
93. Tanghe, A. et al. Tuberculosis DNA vaccine encoding Ag85A is immunogenic and protective when administered by intramuscular needle injection but not by epidermal gene gun bombardment. Infect. Immun. 68, 3854-3860 (2000).
94. Ourmanov, I. et al. Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV. J. Virol. 74, 2740-2751 (2000).
95. Pal, R. et al. ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency. J. Virol. 76, 292-302 (2002).
96. Earl, P. L. et al. Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model. Virology (in the press).
97. McMichael, A. J. et al. The dynamics of the cellular immune response to HIV infection: implications for vaccination. Phil. Trans. R. Soc. Lond. B 355, 1007-1011 (2000).
98. Feinberg, M. B. & Moore, J. P. AIDS vaccine models: challenging challenge viruses. Nature Med. 8, 207-210 (2002).
99. Royce, R. A., Sena, A., Cates, W. J. & Cohen, M. S. Current concepts: sexual transmission of HIV. N. Engl. J. Med. 336, 1072-1078 (1997).
100. Berman, P. W. et al. Genetic and immunologic characterization of viruses infecting MN-rgp120-vaccinated volunteers. J. Infect. Dis. 176, 384-397 (1997).
101. Cunningham, C. K. et al. Safety of two recombinant human immunodeficiency virus type 1 (HIV-1) envelope vaccines in neonates born to HIV-1-infected women. Clin. Infect. Dis. 32, 801-807 (2001).
102. Hanke, T. & McMichael, A. J. Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya. Nature Med. 6, 951-955 (2000).
103. Moss, B. in Fields Virology, Vol. 2 (eds Knipe, D. M. & Howley, P. M.) 2849-2883 (Lippincott, Williams and Wilkins, Philadelphia, 2001).
104. Ramirez, J. C., Gherardi, M. M. & Esteban, M. Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine. J. Virol. 74, 923-933 (2000).
105. + T-cell responses by a DNA-SIV and NYVAC-SIV prime/boost regimen. J. Immunol. 167, 7180-7191 (2001).
106. Tartaglia, J. et al. Highly attenuated poxvirus vectors. AIDS Res. Hum. Retroviruses 8, 1445-1447 (1992).
107. Plotkin, S. A. et al. The safety and use of canarypox vectored vaccines. Dev. Biol. Stand. 84, 165-170 (1995).
108. Paoletti, E. Applications of pox virus vectors to vaccination: an update. Proc. Natl Acad. Sci. USA 93, 11349-11353 (1996).
109. Belshe, R. B. et al. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group. AIDS 12, 2407-2415 (1998).
110. Shenk, T. E. in Fields Virology, Vol. 2 (eds Knipe, D. M. & Howley, P. M.) 2265-2300 (Lippincott, Williams and Wilkins, Philadelphia, 2001).
111. Griffin, D. E. in Fields Virology, Vol. 2 (eds. Knipe, D. M. & Howley, P. M.) 917-962 (Lippincott, Williams and Wilkins, Philadelphia, 2001).
112. Rose, J. K. & Whitt, M. A. in Fields Virology, Vol. 2 (eds Knipe, D. M. & Howley, P. M.) 1221-1244 (Lippincott, Williams and Wilkins, Philadelphia, 2001).
113. Roizman, B. & Knipe, D. M. in Fileds Virology, Vol. 2 (eds. Knipe, D. M. & Howley, P. M.) 2399-2460 (Lippincott, Williams and Wilkins, Philadelphia, 2001).
114. Crotty, S. et al. Protection against simian immunodeficiency virus vaginal challenge by using Sabin poliovirus vectors. J. Virol. 75, 7435-7552 (2001).
115. Freed, E. O. HIV-1 gag proteins: diverse functions in the virus life cycle. Virology 251, 1-15 (1998).
116. McCutchan, F. E. in The Molecular Epidemiology of Infectious Diseases (ed. Thompson, R. C. A.) 143-167 (Hodder Arnold, London, 2000).
117. Amara, R. R. et al. Critical role for Env as well as Gag-Pol for the control of a pathogenic SHIV-89.6P challenge by a DNA/rMVA vaccine. J. Virol. (in the press).